This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and returithe original message to us at the address shown below via the Postal Service. Thank You.

RECEIVED

ALSTON&BIRD LLP

JUL 07 2008

PCT LEGAL ADMINISTRATION 3201 Beechleaf Court, Suite 600 Raleigh, NC 27604-1062

> Tel: 919-862-2200 Fax: 919-862-2260

TELECOPY PLEASE DELIVER AS SOON AS POSSIBLE

Date: Our Ref. July 7, 2008 035784/309941 Recipient: Company: Kaya L. Lewis Baltimore U.S. Patent and Trademark Office PCT Legal Office Fax Number: Voice Number: (571) 273-0459 (571) 272-4300 Sender: Tel: (919) 862-2229 - Fax (919) 862-2260 Leslie T. Henry E-Mail: leslic.henry@alston.com cc: diann.gravius@alston.com Application No.: 10/576,943 Confirmation No. 1890

Application No.: 10/576,943 Confirmation No. 1890

Filed: December 1, 2006 Group Art Unit: 1641

For: USE OF ANTAGONIST ANTI-CD40 ANTIBODIES FOR TREATMENT OF

AUTOIMMUINE AND INFLAMMATORY DISEASES

We are in receipt of a Corrected Filing Receipt and Notice of Acceptance dated June 26, 2008 for the ab ivereferenced National Stage Application. We had made previous requests to correct the Domestic priority data dating back to August of 2007. The priority data was finally correctly updated, however, upon inspection of the documents, we noticed that that <u>I.A. Filing Date of November 4, 2004</u> had been changed to May 19, 2005 on both the filing receipt and notice of acceptance. We note that the May 19, 2005 date is the publication date of the International application. Kindly correct the International Filing date to reflect November 4, 2004 on both the filing receipt and notice of acceptance. This is the only change that show d be made at this time.

We have enclosed copies of the corrected filing receipt and notice of acceptance issued on June 26, 200; showing the *incorrect* International filing date as well as previously issued copies of these documents showing the *correct* international filing date of November 4, 2004. We have also included the 1st page of the publication of the PCT application showing the International filing date of November 4, 2004.

Respectfully submitted, /leslie t. henry/ Leslie T. Henry (45,714) Tel: (919) 862-2229

Number of Pages: (including cover page) 12

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT 862-2221

1		1 LL 1 711 0U2-2421.		
	USER CODE:	GRAVD	REQUESTED BY:	Diann Gravius
l	CLIENT/MATTER:	035784/309941	OPERATOR:	



CHARLOTTE, NC 28280-4000

826

<u>United States Patent and Trademark Office</u>

UNITED STATES DEPARIMENT OF COMMERC United Hatter Palmor and Tendemore United Address COMMISSIONER FOR PATENTS PO. Bux 1450 Alexandra Warner 2731-1440

Alexandra, Virgina 27313-1430

FILING RECEIPT

APPLICATION 191.ING or 171.(c) DATE 11011 1-11.1-12: REC'D APTYLOCKELNO 107 CLAIMS IND CLA MS 10/576,943 12/01/2006 1641 1680 035784/309941 19 5

CONFIRMATION NO. 1. 90

ALSTON & BIRD LLP BANK OF AMERICA PLAZA 101 SOUTH TRYON STREET, SUITE 4000

Date Mailed: 06/26/2008

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DAE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collect on. Please verify the accuracy of the date presented on this receipt. If an error is noted on this Filling Receipt, please submit a written request for a Filling Receipt Correction. Please provide a copy of this Filling Receipt with he changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filling Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filling Receipt incorporating the requested corrections

Applicant(s)

Li Long, Emeryville, CA; Mohammad Luqman, Danville, CA; Asha Yabannavar, Lafayette, CA; Isabel Zaror, Emeryville, CA;

Assignment Fo Published Patent Application

Chiron Corporation, Emeryville, CA

Power of Attorrey: The patent practitioners associated with Customer Number 00826

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US2004/036957 05/19/2005 which claims benefit of 60/517,337 11/04/2003 and claims benefit of 60/525,579 11/26/2003 and claims benefit of 60/565,710 04/27/2004

Foreign Applications

If Required, Foreign Filing License Granted: 08/22/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 10/576,943**

Projected Publication Date: 10/02/2008

Non-Publication Request: No Early Publication Request: No

page 1 of 3

Title

Use of Antagonist Anti-CD40 Antibodies for Treatment of Autoimmune and Inflammatory Diseases and Organ Transplant Rejection

Preliminary Class

424

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an internatic rall application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the fing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO in ist issue a license before applicants can apply for a patent in a foreign country. The filling of a U.S. patent application on serves as a request for a foreign filling license. The application's filling receipt contains further information; and guidance as to the status of applicant's license for foreign filling.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing fore gn patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or the can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants rilay call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILI IG LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where page 2 of 3

the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification.

date indicated is the effective date of the license, unless an earlier license of similar scope has been granted unler

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unities it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

37 CFR 5.13 or 5.14.

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILLING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5 12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



<u>United States Patent and Trademark Office</u>

UNITED STATES DEPARTMENT OF COMMERC United States Fasent and Trademark Office Aware Commissionals Post Patent's Office 1450 Alexandra, Viguro 22313-1150

U.S. APPLIC A ITON NUMBER NO.	PRST NAMED APPLICANT	Alt	APTY, DOCKET NO.		
10/576,943	Li Long	035784/309941 INIERNATIONAL APPLICATION NO. PC1/US2004/036957			
826					
ALSTON & BIRD LLP					
BANK OF AMERICA PLAZA	should be: [I.A. FILING DATE	PRIORITY DAT		
101 SOUTH TRYON STREET, SUITE 4000	11/4/2004	-05/19/200 5	11/04/2003		
CHARLOTTE, NC 28280-4000	11/4/2009 14				

CONFIRMATION NO. 1: 90 371 ACCEPTANCE LETT: R



Date Mailed 06/26/2008

NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.49

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495), has determined that the above identified international application I as met the requirements of 35 U.S.C. 371, and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.

The United States Application Number assigned to the application is shown above and the relevant dates are:

12/01/2006

DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) REQUIREMENTS

12/01/2006

DATE OF COMPLETION OF ALL 35 U.S.C. 371 REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. THE DATE APPÈARING ON THE FILING RECEIPT AS THE "FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C 371 (c)(1), (c)(2) and (c)(4) REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE. The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363). Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

The following items have been received:

- Copy of the International Application filed on 04/21/2006
- Copy of the International Search Report filed on 04/21/2006
- Preliminary Amendments filed on 04/21/2006
- Information Disclosure Statements filed on 04/21/2006
- Biochemical Sequence Diskette filed on 04/21/2006
- Oath or Declaration filed on 12/01/2006
- Biochemical Sequence Listing filed on 04/21/2006
- Request for Immediate Examination filed on 04/21/2006
- Copy of references cited in ISR filed on 04/21/2006
- U.S. Basic National Fees filed on 04/21/2006
- Priority Documents filed on 04/21/2006
- Specification filed on 04/21/2006
- Claims filed on 04/21/2006
- Drawings filed on 04/21/2006

page 1 of 2

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

KAYA L LEWIS BALTIMORE

Telephone: (703) 308-9140 EXT 202

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PC I)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 19 May 2005 (19.05.2005)

(10) International Publication Number WO 2005/044306 A3

- (51) International Patent Classification?: A61P 37,06, 29/00 // C07K 16/28
- A61K 39/395,
- (21) International Application Number:

Ilmeryville, CA 94662-8097 (US).

PCT/US2004/036957

(22) International Filing Date:

4 November 2004 (04.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/517,337 60/525.5"9

4 November 2003 (04.11.2003) US 26 November 2003 (26.11.2003) US

60/565,7 0

27 April 2004 (27.04.2004) US

- (71) Applicant (for all designated States except (1/S): CHI-RON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608-2916 (US).
- (72) Inventor;; and
- (75) Inventor Applicants (for US only): LONG, Li [CA/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US). LUQMAN, Mohammad [US/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US). YABANNAVAR, Asha [US/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US). ZAROR, Isabel [US/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US).

(74) Agents: ALEXANDER, Lisn, E. et al.; Chiron Corporation, Intellectual Property Department, P.O. Bo 8097,

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, A ., AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, C II, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, IP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, M \, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, C M, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, ' J, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, Z 1, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARTPO (B V, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, U J, ZM, ZW), Rurasian (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, O, SE, SI, SK, TR), OAPI (BE, BJ, CF, CG, CI, CM, GA, CN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (88) Date of publication of the international search report: 15 Septemb r 2005

For two-letter codes and other abbreviations, refer to the "Guid ance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF ANTAGONIST ANTI-CD40 ANTIBODIUS FOR TREATMENT OF AUTOIMMUNE AND INFLAMMA-TORY DISEASES AND ORGAN TRANSPLANT REJECTION

(57) Abstract: Methods of therapy for treating a subject for an autoimmune disease and/or inflammatory disease are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40- expressing cill. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits CD401,-mediated stin ulation of CD40-expressing cells, and thus inhibits survival and signaling pathways of human CD40-expressing cells that are med ated by CD401...





Uijited States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United Histon Palent and Trademark Office Address CARATESIONER (OR PATENTS FORESTORM AUGUST 22015-7430 Workship, Vignia 22015-7430

FILING or 371(c) APPLICATION N JMBER GRP ART UNIT FIL FEE REC'D ATTY.DOCKET.NO TOT CLAIMS INE CLAIMS 1680 035784/309941 19 5

10/576,943

1641

12/01/2006

826

ALSTON & BIRD LLP BANK OF AMERICA PLAZA 101 SOUTH TRYON STREET, SUITE 4000

CHARLOTTE, INC28280-4000

FILING RECEIPT

Date Mailed: 09/21/2007

his is correct cate.

CONFIRMATION NO. 1890

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information; the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Li Long, Emeryville, CA; Mohammad Lugman, Danville, CA; Asha Yabannavar, Lafayette, CA; Isabel Zaror, Emeryville, CA;

Assignment For Published Patent Application

Chiron Corporation, Emeryville, CA

Power of Attorney: The patent practitioners associated with Customer Number 00826

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/36957(11/04/2004 which claims benefit of 60/517,337 11/04/2003

and claims benefit of 60/525,579 11/26/2003X and claims benefit of 60/565,710 04/27/2004X

Data provided by applicant is not consistent with PTO records.

Foreign Applications

if Required, Foreign Filing License Granted: 08/22/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convent on, is US10/576,943

Projected Publication Date: 12/27/2007

Non-Publication Request: No

Early Publication Request: No

Title

Use of Antagonist Anti-CD40 Antibodies for Treatment of Autoimmune and Inflammatory Diseases and Organ Transplant Rejection

Preliminary Class

424

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a fc reign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign palent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to

revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless i; is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)) the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still pelition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

Page 1 cf2



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERC United States Potent and Trademark Office Address COMMISSIONER FOR PATENTS 60, 621 1450 Advances, Vignis ID13-1459 Pyrespector

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	• .]	ATTY, DOCKET NO		
/ 10/576,943	Li Long	035784/309941 INTERNATIONAL APPLICATION NO.		784/309941	
Previously Issued notice of Acceptance	•			PLICATION NO.	
BED notice of Acceptance	•	PCT/US04/36957			
ALSTON & BIRE LLP		I.A. FILT	MOTIVIE	PRIORITY DAT	
BANK OF AMERICA PLAZA 101 SOUTH TRYON STREET, SUITE 4000	This is correct Acide	> 11/04	/2004	11/04/200	
CHARLOTTE, NC 28280-4000		CONFIRMATION NO. 1890			
		371 ACCE			
	•	*OC0000000			

Date Mailed: 08/1:4/2007

NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.49 5

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.

The United States Application Number assigned to the application is shown above and the relevant dates are:

12/01/2006

DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) REQUIREMENTS

12/01/2006

DATE OF COMPLETION OF ALL 35 U.S.C. 371
REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. THE DATE APPEARING ON THE FILING RECEIPT AS THE "FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C 371 (c)(1), (c)(2) and (c)(4) REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOVIN ABOVE. The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363). Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

The following items have been received:

- Copy of the International Application filed on 04/21/2006
- Copy of the International Search Report filed on 04/21/2006
- Preliminary Amendments filed on 04/21/2006
- Information Disclosure Statements filed on 04/21/2006
- Biochemical Sequence Diskette filed on 04/21/2006
- Oath or Declaration filed on 12/01/2006
- Biochemical Sequence Listing filed on 04/21/2006
- Request for Immediate Examination filed on 04/21/2006
- Copy of references cited in ISR filed on 04/21/2006
- U.S. Basic National Fees filed on 04/21/2006
- Priority Documents filed on 04/21/2006

Page 2 cf 2

- Spécificat on 04/21/2006
- Claims filed on 04/21/2006
- Drawings filed on 04/21/2006

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

KAYA L LEWIS BALTIMORE Telephone: (703) 308-9140 EXT 202

PART 3 - OFFICE COPY

FORM PCT/DO/EO/5103 (371 Acceptance Notice)

RX REPORT

RECEPTION OK

TX/RX NO

5847

RECIPIENT ADDRESS

DESTINATION ID

ST. TIME

07/07 15:25

TIME USE PGS.

01'34

RESULT

12

OK